Abstract
With the new direct oral anticoagulants (NOAC) - apixaban, dabigatran, rivaroxaban and edoxaban - already been gained more practical experience, which are now listed in the updated recommendations. This relates to the possibility of using a specific antidote to dabigatran idarucizumabu in bleeding, procedures for discontinuation of NOACs, concomitant therapy with antiplatelet drugs and others.
In the extended prophylaxis of venous thromboembolism (VTE) in immobile patients with acute medical illness could be used new F Xa inhibitor betrixiban, which is now designed for registration